Researchers find comparable long-term outcomes between diastolic and systolic heart failure patients

January 09, 2014

(Boston) - A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as "diastolic heart failure" and congestive heart failure with reduced ejection fraction also known as "systolic heart failure." The findings are published online in The American Journal of Cardiology.

Patients with normal percentage of blood leaving the heart each time it contracts and symptoms of heart failure are considered to have diastolic heart failure. Diastolic heart failure patients have not been as well studied as patients with systolic heart failure. Systolic heart failure patients have impaired blood ejection with each contraction of the heart, and do not derive long term benefit from the same medications.

According to the researchers, heart failure affects six million people in the U.S. alone and half of those admissions are patients with diastolic heart failure. However, there are not yet any treatments for this condition. In addition, the number of people who will develop diastolic heart failure is expected to rise as the population ages and the incidence of obesity and hypertension increases.

"An incredible amount of expensive and time-consuming resources are being spent on reducing readmissions at a national level, but have not translated into a reduction in heart failure mortality," said senior author Flora Sam, MD, associate professor of cardiovascular medicine at the Whitaker Cardiovascular Institute at BUSM and attending physician of cardiovascular medicine and heart failure at BMC.

The researchers gathered patient data from all heart failure admissions over a two-year period at BMC. Using the American Heart Association's Get-With-the-Guidelines quality improvement program, patients were reviewed for co-morbid conditions including kidney function, blood counts, and blood tests such as brain natriuretic peptide (BNP), a marker of heart failure.

The findings showed that in comparison to those with systolic heart failure, diastolic heart failure patients were older, more likely to be overweight, female and have hypertension. The one-year outcome of in-hospital morbidity and mortality was similar between diastolic and systolic heart failure patients. Though the early readmission rate in the 30 days after discharge was initially lower in patients with diastolic heart failure, this soon increased such that it was similar to those with systolic heart failure.

"This study shows the importance of refocusing our attention and resources on medication trials, which have historically reduced adverse long-term outcomes in chronic heart failure patients. Exploring medicinal treatment options for diastolic heart failure patients could potentially reduce readmissions, morbidity, mortality and long-term healthcare costs," said Sam.
-end-


Boston University Medical Center

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.